Núñez Julio, Miñana Gema, de la Espriella Rafael, Zegrí-Reiriz Isabel, Comín-Colet Josep, Rubio Gracia Jorge, Morales-Rull Jose Luis, Llàcer Pau, Diez-Villanueva Pablo, de Juan Bagudá Javier, Ortiz Cortés Carolina, Goirigolzarri-Artaza Josebe, García-Pinilla Jose Manuel, Barrios Elvira, Del Prado Díaz Susana, Jiménez-Marrero Santiago, Restrepo-Córdoba Maria Alejandra, Testani Jeffrey, Cobo Marcos Marta
Cardiology Department, Hospital Clínico Universitario de Valencia (INCLIVA), University of Valencia, Valencia, Spain.
Centro de Investigación Biomédica en Red (CIBER) Cardiovascular, Madrid, Spain.
Eur J Heart Fail. 2025 Jun;27(6):960-971. doi: 10.1002/ejhf.3597. Epub 2025 Feb 11.
The efficacy of combining hypertonic saline solution (HSS) with loop diuretics in worsening heart failure (WHF) remains uncertain. Hypochloraemia has been associated with reduced diuretic efficacy. Some authors propose that chloride repletion may enhance natriuretic and diuretic responses. This post-hoc analysis of the SALT-HF trial evaluated the effect of single-dose administration of HSS plus intravenous (IV) furosemide versus IV furosemide, stratified by baseline serum chloride.
The analysis included 148 ambulatory patients with WHF from the double-blind, randomized SALT-HF trial. Participants received either an IV single dose of HSS plus furosemide or IV furosemide. The endpoints were 3-h urinary sodium excretion and diuresis, 7-day congestion score, and 30-day adverse events according to chloride levels. Multivariable linear and logistic regression models assessed the relationship between the intervention and the endpoints. The mean baseline serum chloride level was 100 ± 4 mmol/L. Sixteen patients (10.8%) were identified as hypochloraemic (serum chloride <96 mmol/L), balanced between treatment groups. Patients with hypochloraemia showed a lower natriuretic response (p < 0.05). Interaction analysis revealed a between-treatment differential natriuretic effect based on the chloride levels (p = 0.008). HSS plus furosemide increased natriuresis compared to furosemide at lower chloride levels. No differential between-treatment effect was found for 3-h diuresis. Similar heterogeneous results were found for the 7-day clinical congestion score and 30-day heart failure events, with a benefit with HSS in patients with lower chloride levels.
In ambulatory patients with WHF and hypochloraemia, adding HSS to furosemide may improve short-term natriuretic response and outcomes. These findings suggest that chloride supplementation may help overcome diuretic resistance in these patients.
高渗盐溶液(HSS)与袢利尿剂联合应用于失代偿性心力衰竭(WHF)的疗效仍不确定。低氯血症与利尿剂疗效降低有关。一些作者提出补充氯化物可能增强利钠和利尿反应。这项对SALT-HF试验的事后分析评估了单剂量给予HSS加静脉注射(IV)呋塞米与IV呋塞米相比的效果,并根据基线血清氯化物进行分层。
该分析纳入了双盲、随机SALT-HF试验中的148例非卧床WHF患者。参与者接受IV单剂量HSS加呋塞米或IV呋塞米。终点指标为3小时尿钠排泄量和尿量、7天充血评分以及根据氯化物水平评估的30天不良事件。多变量线性和逻辑回归模型评估了干预措施与终点指标之间的关系。平均基线血清氯化物水平为100±4 mmol/L。16例患者(10.8%)被确定为低氯血症(血清氯化物<96 mmol/L),在治疗组之间分布均衡。低氯血症患者的利钠反应较低(p<0.05)。交互分析显示基于氯化物水平的治疗间利尿钠效应存在差异(p = 0.008)。在较低氯化物水平时,HSS加呋塞米与呋塞米相比增加了尿钠排泄。3小时尿量未发现治疗间差异效应。7天临床充血评分和30天心力衰竭事件也发现了类似的异质性结果,在氯化物水平较低的患者中HSS有益。
在非卧床WHF和低氯血症患者中,在呋塞米中添加HSS可能改善短期利钠反应和结局。这些发现表明补充氯化物可能有助于克服这些患者的利尿剂抵抗。